Tarsus Pharmaceuticals (TARS) Insider Phd Buys 2,954 Shares
Link William Phd acquired 2,954 shares of TARS on June 12, 2026, as part of insider trading activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
Link William Phd bought 2,954 shares of Tarsus Pharmaceuticals, Inc. ($TARS) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $TARS is up 2.6% after 1 week, down 4.3% after 1 month and up 9.9% to date (from the $61.95 close on Jun 12, 2026).
TARS
Tarsus Pharmaceuticals, Inc.
Key Points
- Link William Phd bought 2,954 shares of TARS on June 12, 2026, with no planned transaction code.
- TARS shares traded at $61.85, with a strong buy consensus among analysts and price targets reaching $105.
- Institutional investors like Deep Track Capital and Janus Henderson Group adjusted their TARS holdings significantly.
Get $TARS trade alerts by text
We text you when insiders, Congress or big funds trade $TARS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tarsus Pharmaceuticals, Inc. alert may contain errors. Disclosures
On June 12, 2026, Link William Phd made a move in the stock market by purchasing 2,954 shares of TARS. This insider transaction was not pre-planned, indicating a direct acquisition of shares. The purchase adds to the ongoing activity among TARS insiders.
Other Institutional Activity in TARS
Several institutional investors have been adjusting their positions in TARS. Deep Track Capital increased its holdings by 595,966 shares, ending with 3.6 million shares valued at approximately $252.54 million. Meanwhile, BlackRock, Inc. reduced its stake by 237,945 shares, bringing its total to about 3.55 million shares worth $249.22 million. RTW Investments, LP made a smaller addition of 10,705 shares, now holding 3.35 million shares valued at $234.72 million. Paradigm Biocapital Advisors LP maintained its position with 2.56 million shares valued at $179.74 million. Janus Henderson Group added 310,638 shares, reaching 2.24 million shares worth $157.22 million.
Tarsus Pharmaceuticals, Inc. Stock Down 20.8%
Shares of TARS were trading at $61.85. The stock has been under the spotlight with several analysts maintaining a positive outlook. The market activity and institutional interest reflect the ongoing confidence in TARS's performance.
Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.
On June 12, 2026, insider transactions included several buys and sells. Wendy Yarno bought 2,954 shares, while Bhaskar Chaudhuri and Andrew Goldberg each sold 2,954 shares. These transactions were not part of any planned trading programs.
Analysts Set New Price Targets
Analyst firms have shown a strong buy consensus for TARS. On May 4, 2026, HC Wainwright & Co. reiterated its buy rating with a price target of $88. Oppenheimer and Guggenheim maintained their buy ratings earlier in the year, with targets of $105 and $90, respectively. Barclays initiated coverage with a buy rating and a $100 target in December 2025.
Bottom Line
Link William Phd's purchase of TARS shares highlights ongoing insider interest in the company. With analysts maintaining high price targets and institutional investors adjusting their positions, TARS remains a closely watched stock. These insider transactions provide a glimpse into the confidence levels of those closest to the company, although they do not necessarily predict future stock performance.
Related Filing Alerts
Source: Link William Phd's Form 4 filing on $TARS (Jun 12, 2026). Find the original filing: TARS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts